[go: up one dir, main page]

CY1117639T1 - Φαρμακευτικες συνθεσεις βασιζομενες επι κρυσταλλικης μορφης i της 5-αζακυτιδινης - Google Patents

Φαρμακευτικες συνθεσεις βασιζομενες επι κρυσταλλικης μορφης i της 5-αζακυτιδινης

Info

Publication number
CY1117639T1
CY1117639T1 CY20161100474T CY161100474T CY1117639T1 CY 1117639 T1 CY1117639 T1 CY 1117639T1 CY 20161100474 T CY20161100474 T CY 20161100474T CY 161100474 T CY161100474 T CY 161100474T CY 1117639 T1 CY1117639 T1 CY 1117639T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
azakytidine
crystal form
compositions based
azacytidine
Prior art date
Application number
CY20161100474T
Other languages
English (en)
Inventor
Dumitru Ionescu
Peter Blumbergs
Lee Alani Selvey
Original Assignee
Celgene International Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32987551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117639(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene International Sarl filed Critical Celgene International Sarl
Publication of CY1117639T1 publication Critical patent/CY1117639T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση περιλαμβάνει μεθόδους για απομόνωση κρυσταλλικής Μορφής I της 5-αζακυτιδίνης ουσιαστικώς ελεύθερη άλλων μορφών. Η εφεύρεση επίσης περιλαμβάνει φαρμακευτικές συνθέσεις που περιλαμβάνουν Μορφή I της 5-αζακυτιδίνης.
CY20161100474T 2003-03-17 2016-05-31 Φαρμακευτικες συνθεσεις βασιζομενες επι κρυσταλλικης μορφης i της 5-αζακυτιδινης CY1117639T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/390,530 US6943249B2 (en) 2003-03-17 2003-03-17 Methods for isolating crystalline Form I of 5-azacytidine
EP10151392.7A EP2181988B1 (en) 2003-03-17 2004-03-16 Pharmaceutical Compositions based on Crystalline Form I of 5-Azacytidine

Publications (1)

Publication Number Publication Date
CY1117639T1 true CY1117639T1 (el) 2017-04-26

Family

ID=32987551

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100700T CY1114213T1 (el) 2003-03-17 2013-08-14 Μεθοδοι απομονωσης κρυσταλλικης μορφης ι της 5-αζακυτιδινης
CY20161100474T CY1117639T1 (el) 2003-03-17 2016-05-31 Φαρμακευτικες συνθεσεις βασιζομενες επι κρυσταλλικης μορφης i της 5-αζακυτιδινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131100700T CY1114213T1 (el) 2003-03-17 2013-08-14 Μεθοδοι απομονωσης κρυσταλλικης μορφης ι της 5-αζακυτιδινης

Country Status (16)

Country Link
US (5) US6943249B2 (el)
EP (3) EP1608634B1 (el)
JP (1) JP4792550B2 (el)
AU (2) AU2004222274B2 (el)
BR (1) BRPI0408506A (el)
CA (1) CA2518973A1 (el)
CY (2) CY1114213T1 (el)
DK (2) DK1608634T3 (el)
EC (1) ECSP056023A (el)
ES (2) ES2425474T3 (el)
HU (1) HUE028268T2 (el)
MX (1) MXPA05009969A (el)
PL (2) PL2181988T3 (el)
PT (2) PT2181988E (el)
SI (2) SI2181988T1 (el)
WO (1) WO2004082822A2 (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8902490A (nl) * 1989-10-06 1991-05-01 Leonardus Mathijs Marie Nevels Werkwijze voor het reinigen van rookgassen.
DE60116318T2 (de) * 2001-10-08 2006-08-31 Alcatel Verfahren zur Lastverteilung zwischen mehreren gemeinsamen Betriebsmitteln in einem Kommunikationsnetzwerk und Netzwerk zur Anwendung des Verfahrens
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
US7759481B2 (en) * 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
EP2176279A4 (en) * 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
CA2700207A1 (en) * 2007-09-26 2009-04-02 Mount Sinai School Of Medicine Azacytidine analogues and uses thereof
US20100311683A1 (en) * 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
CL2009001170A1 (es) 2008-05-15 2010-06-04 Celgene Corp Composicion farmaceutica para administracion oral que comprende 5-azacitidina de liberacion inmediata sin recubrimiento enterico; y su uso para el tratamiento de una enfermedad asociada a la proliferacion anormal de celulas, tal como sindrome mielodisplasico, leucemia mielogena aguda y cancer de pulmon, entre otros.
WO2010014883A2 (en) 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
AU2009279461B2 (en) * 2008-08-08 2014-01-23 Scinopharm Taiwan, Ltd. Process for making 5-azacytosine nucleosides and their derivatives
AR076418A1 (es) * 2009-04-27 2011-06-08 Reddys Lab Inc Dr Preparacion de decitabina
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2012106299A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
RU2013148580A (ru) 2011-03-31 2015-05-10 Селджин Интернешнл Сарл Синтез 5-азацитидина
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
JP2014526558A (ja) 2011-09-23 2014-10-06 セルジーン コーポレイション リンパ腫の治療に使用するためのロミデプシン及び５−アザシチジン
CN104039330A (zh) 2011-09-26 2014-09-10 细胞基因公司 化疗耐药性的癌症的联合治疗
CN104245699B (zh) 2011-11-03 2017-06-27 米伦纽姆医药公司 Nedd8‑活化酶抑制剂和低甲基化剂的投与
WO2013080221A2 (en) * 2011-12-01 2013-06-06 Hetero Research Foundation Process for alvimopan
WO2014064717A1 (en) * 2012-10-25 2014-05-01 Fresenius Kabi Oncology Limited Stable pharmaceutical composition of 5-αζα-2'ρεοχυοτιρινε
WO2014076616A2 (en) * 2012-11-19 2014-05-22 Shilpa Medicare Limited Formulations of 5-azacytidine
US9765108B2 (en) 2012-11-19 2017-09-19 Shilpa Medicare Limited Formulation of 5-azacytidine
WO2014160698A1 (en) 2013-03-26 2014-10-02 Celgene Corporation SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
CN103450303A (zh) * 2013-09-04 2013-12-18 重庆泰濠制药有限公司 阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
US20160095925A1 (en) * 2014-10-01 2016-04-07 Cadila Healthcare Limited Stable formulation of azacitidine or salts thereof and their process for preparation
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
MX2018004586A (es) 2015-10-15 2018-08-16 Agios Pharmaceuticals Inc Terapia de combinacion para tratar tumores malignos.
EP3527226A4 (en) * 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited Combination therapy method using mdm2 inhibitor and dna methyltransferase inhibitor
CN109988207B (zh) * 2017-12-29 2022-01-04 江苏豪森药业集团有限公司 阿扎胞苷晶型的制备方法
CN116059404A (zh) 2018-06-11 2023-05-05 加利福尼亚大学董事会 用以治疗眼睛疾病的脱甲基化
CN110642901A (zh) * 2019-11-11 2020-01-03 扬子江药业集团有限公司 阿扎胞苷甲醇化物及其制备方法和药物组合物、用途
WO2022251663A2 (en) * 2021-05-27 2022-12-01 Emory University Novel universal anti-rna virus agents

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (el) * 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) * 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) * 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) * 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) * 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
BR9712527A (pt) * 1996-10-16 2000-03-08 Icn Pharmaceuticals L-nucleosìdeos monocìclicos, análogos e seus empregos
JP4130078B2 (ja) * 1999-06-03 2008-08-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 カルバペネム誘導体結晶と注射製剤
DE60024830T2 (de) * 1999-07-09 2006-06-14 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2002020453A1 (fr) * 2000-09-07 2002-03-14 Kaneka Corporation Procedes de cristallisation d'acides hydroxycarboxyliques
WO2002070518A1 (en) * 2001-03-01 2002-09-12 Triangle Pharmaceuticals, Inc. Polymorphic and other crystalline forms of cis-ftc
JP2006507255A (ja) * 2002-09-24 2006-03-02 コローニス ファーマシューティカルズ インコーポレイテッド ウイルス疾患の治療のための１，３，５−トリアジン
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CA2503150A1 (en) * 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
WO2004069796A2 (en) * 2003-02-03 2004-08-19 Teva Pharmaceutical Industries Ltd. Process for producing levetiracetam
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6877855B2 (en) 2003-07-08 2005-04-12 Dave Ng Spectacles with peripheral lens support
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20080057086A1 (en) * 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) * 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
EP2114152A1 (en) * 2007-01-25 2009-11-11 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
EP2176279A4 (en) 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
EP2048151A1 (en) * 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
US20100311683A1 (en) * 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
CL2009001170A1 (es) * 2008-05-15 2010-06-04 Celgene Corp Composicion farmaceutica para administracion oral que comprende 5-azacitidina de liberacion inmediata sin recubrimiento enterico; y su uso para el tratamiento de una enfermedad asociada a la proliferacion anormal de celulas, tal como sindrome mielodisplasico, leucemia mielogena aguda y cancer de pulmon, entre otros.
WO2010014883A2 (en) * 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
KR20110026019A (ko) * 2008-08-06 2011-03-14 시코르, 인크. 아자시티딘 중간체의 제조 방법
AU2009279461B2 (en) * 2008-08-08 2014-01-23 Scinopharm Taiwan, Ltd. Process for making 5-azacytosine nucleosides and their derivatives
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) * 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina

Also Published As

Publication number Publication date
US20050272675A1 (en) 2005-12-08
EP2266965A1 (en) 2010-12-29
CA2518973A1 (en) 2004-09-30
CY1114213T1 (el) 2016-08-31
WO2004082822A3 (en) 2005-07-07
SI1608634T1 (sl) 2013-09-30
US20100292180A1 (en) 2010-11-18
US6943249B2 (en) 2005-09-13
PT2181988E (pt) 2016-06-15
US8975392B2 (en) 2015-03-10
ES2425474T3 (es) 2013-10-15
ECSP056023A (es) 2006-01-27
US7700770B2 (en) 2010-04-20
PT1608634E (pt) 2013-08-27
US20130274459A1 (en) 2013-10-17
JP2006523210A (ja) 2006-10-12
BRPI0408506A (pt) 2006-03-14
EP1608634B1 (en) 2013-05-22
US20120245342A1 (en) 2012-09-27
AU2004222274A1 (en) 2004-09-30
US8211862B2 (en) 2012-07-03
AU2004222274B2 (en) 2010-11-04
SI2181988T1 (sl) 2016-09-30
AU2010241198A1 (en) 2010-11-25
EP2181988A1 (en) 2010-05-05
EP1608634A2 (en) 2005-12-28
PL1608634T3 (pl) 2013-10-31
PL2181988T3 (pl) 2016-11-30
DK1608634T3 (da) 2013-08-12
MXPA05009969A (es) 2006-02-17
EP1608634A4 (en) 2006-03-15
ES2575535T3 (es) 2016-06-29
HUE028268T2 (en) 2016-12-28
DK2181988T3 (en) 2016-06-06
WO2004082822A2 (en) 2004-09-30
EP2181988B1 (en) 2016-05-11
US8481715B2 (en) 2013-07-09
AU2010241198B2 (en) 2012-05-10
JP4792550B2 (ja) 2011-10-12
US20040186284A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
CY1117639T1 (el) Φαρμακευτικες συνθεσεις βασιζομενες επι κρυσταλλικης μορφης i της 5-αζακυτιδινης
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
CY1117990T1 (el) Μορφες 5-αζακιτιδινης
SE0301372D0 (sv) Novel compounds
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
IL175512A0 (en) Methods of preparing aripiprazole crystalline forms
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
NO20090175L (no) Stabile laquinimod sammensetninger
NO20071078L (no) Antivirale forbindelser
NO20070866L (no) Antivirale forbindelser.
ECSP045088A (es) Forma polimorfica de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
SE0101675D0 (sv) Novel composition
CU23615B7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
NO20090596L (no) Antivirale fosfinatforbindelser
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
NO20063293L (no) Farmasoytiske forbindelser
NO20060896L (no) Alfa-aminoamidderivater nyttige som antiinflammatoriske midler
CY1108226T1 (el) Αντικαρκινικες ενωσεις βασισμενες σε καχαλαλιδης f
RS20050649A (en) Antibacterial indolone oxazolidinones,intermediates for their preparation and pharmaceutical compositions containing them
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser